Foursixthree Capital LP Makes New Investment in Indivior PLC (NASDAQ:INDV)

Foursixthree Capital LP acquired a new stake in Indivior PLC (NASDAQ:INDV - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 373,231 shares of the company's stock, valued at approximately $4,639,000. Indivior makes up about 1.6% of Foursixthree Capital LP's portfolio, making the stock its 8th biggest holding. Foursixthree Capital LP owned 0.27% of Indivior as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Jane Street Group LLC grew its stake in shares of Indivior by 101.9% during the 4th quarter. Jane Street Group LLC now owns 36,881 shares of the company's stock worth $473,000 after acquiring an additional 18,611 shares in the last quarter. PDT Partners LLC grew its position in Indivior by 4.7% in the fourth quarter. PDT Partners LLC now owns 57,520 shares of the company's stock valued at $715,000 after purchasing an additional 2,596 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Indivior in the 4th quarter valued at $1,686,000. Tudor Investment Corp ET AL increased its stake in Indivior by 113.1% in the 4th quarter. Tudor Investment Corp ET AL now owns 45,478 shares of the company's stock valued at $565,000 after buying an additional 24,137 shares during the last quarter. Finally, Melqart Asset Management UK Ltd lifted its position in Indivior by 675.6% during the 4th quarter. Melqart Asset Management UK Ltd now owns 104,790 shares of the company's stock worth $1,303,000 after buying an additional 91,280 shares in the last quarter. 60.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Piper Sandler decreased their price target on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. Finally, Rodman & Renshaw began coverage on Indivior in a research note on Tuesday, January 28th. They set a "buy" rating and a $16.00 price objective on the stock.

Indivior Trading Up 3.7 %

Shares of Indivior stock traded up $0.43 during trading on Friday, hitting $11.98. 914,871 shares of the stock were exchanged, compared to its average volume of 985,869. The company has a fifty day moving average price of $9.75 and a 200-day moving average price of $10.45. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -34.23 and a beta of 0.93. Indivior PLC has a 1-year low of $7.33 and a 1-year high of $18.59.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The firm had revenue of $266.00 million for the quarter, compared to the consensus estimate of $240.13 million. Equities research analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.